Search

The US Food and Drug Administration (FDA) has expanded the approval of dostarlimab-gxly (Jemperli, GSK) for the treatment of primary advanced or recurrent endometrial cancer. The approval is now granted for the use of dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly. This expanded approval was based on the results of the RUBY trial, which showed improved overall survival and progression-free survival in patients receiving dostarlimab-gxly. Common adverse reactions to the treatment include anemia, peripheral neuropathy, fatigue, and nausea. The recommended dosing regimen is outlined in the prescribing information. [Extracted from the article]

A study published in Pediatric News compared the effectiveness of three cycles versus six cycles of chemotherapy for high-risk retinoblastoma. The research found that three cycles showed noninferior 5-year disease-free survival rates, with fewer adverse events and lower costs. The study, led by Huijing Ye, MD, PhD, was published in JAMA and could potentially impact clinical practice by reducing treatment burden and costs without compromising patient outcomes. [Extracted from the article]

A study presented at the American Society of Clinical Oncology annual meeting found that hormone receptor positivity does not have a strong positive prognostic value in young women with BRCA-associated breast cancer. The study, which reviewed the records of 4709 women with BRCA-associated breast cancer, found that hormone receptor-positive breast cancer appears to be biologically more aggressive in patients with BRCA pathological variants (PVs) than in the general breast cancer population. The study also found differences in recurrence patterns and second primary breast cancer rates between hormone receptor-positive and hormone receptor-negative disease in young BRCA carriers. The researchers concluded that these differences should be considered when counseling patients on treatment, follow-up, and risk-reducing surgery. [Extracted from the article]

The American Society of Clinical Oncology (ASCO) has provided guidance on the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, specifically abemaciclib and ribociclib, for the adjuvant treatment of stage II and III breast cancer. The guideline recommends abemaciclib for 2 years plus endocrine therapy (ET) for at least 5 years for patients with resected, hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. Ribociclib (400 mg once daily, 3 weeks on, 1 week off) for 3 years plus ET is recommended for patients with stage II or III breast cancer who have a high risk of recurrence. The decision between the two drugs should consider factors such as benefits, risks, costs, and individual patient preferences. However, it is important to note that the clinical benefits of adjuvant CDK4/6 inhibitor therapy may not extend to all eligible patients, and more data is needed to provide long-term efficacy data and more detailed guidance on specific patient populations that will benefit most from this therapy. [Extracted from the article]

Cutaneous immune-related adverse events are associated with improved overall and progression-free survival among patients treated with immune checkpoint inhibitors (ICIs). The major outcomes evaluated in the analysis were overall survival and progression-free survival (PFS); subgroup analyses assessed cutaneous immune-related adverse event type, cancer type, and other factors. Among patients with melanoma, analyses revealed a significant association between the incidence of cutaneous immune-related adverse events and improved overall survival (HR, 0.51) and PFS (HR, 0.45). [Extracted from the article]

The article discusses research which suggests that biochemical recurrence (BCR) falls short as a reliable surrogate for overall survival in localized prostate cancer trials and may not be a suitable primary endpoint in randomized trials conducted for localized prostate cancer. The study examined the treatment effect of BCR, mortality risk for radiotherapy dose escalation, risk for short-term androgen deprivation therapy (ADT) and ADT prolongation.

The article discusses research published in the New England Journal of Medicine, which demonstrates that the immunotherapy drug blinatumomab improves outcomes in infants with KMT2A-rearranged acute lymphoblastic leukemia (ALL) when added to standard chemotherapy. The study showed higher rates of disease-free and overall survival, as well as a reduction in relapse rates, compared to historical controls, suggesting that blinatumomab could be a promising addition to treatment for infants.

The article discusses research presented at the ESMO Breast Cancer annual congress, by Guilherme Nader Marta, MD, of the Institut Jules Bordet, Anderlecht, Belgium,which conducted a meta-analysis and systematic review on the association between circulating tumor DNA (ctDNA) and outcomes in early breast cancer patients. The study found that the detection of ctDNA at various time points was significantly linked to worse disease-free survival and overall survival.

The article discusses research by Senna W.M. Lammers, MD, and colleagues, reported at the ESMO Breast Cancer 2023 conference, on the prognostic and predictive effect of body mass index (BMI) on disease-free survival (DFS) in postmenopausal women with hormone receptor-positive breast cancer.The study found that while overweight and obesity were overall predictors of lower DFS, BMI had no apparent association with the effect of extended endocrine therapy on DFS.

The article focuses on the enhanced response seen in triple-negative breast cancer patients with the addition of atezolizumab to chemotherapy. The study showed significant improvement in pathological complete response (pCR) and promising outcomes in event-free survival; disease-free survival; and overall survival; and also indicating the potential of immunotherapy in the treatment of these patients.

The article reports on the study entitled "How healthy are the children of Indian Sunderbans?" by Indian Institute of Health Management Research (IIHMR) University based in Rajasthan, India which reveals that the children in the region have survived by chance.

The article offers author's insights on her experience as a cancer survival where various words remains obscure like refractory, relapsed, and seeded, and mentioned her oncologist call her an exceptional responder.